You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • SAT0329 Lesinurad, A Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout: the Crystal Phase III Clinical Trial

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Bone diseases other than osteoporosis, metabolic diseases and crystal diseases
SAT0329 Lesinurad, A Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout: the Crystal Phase III Clinical Trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Dalbeth N, Jones G, Terkeltaub R, et al
SAT0329 Lesinurad, A Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout: the Crystal Phase III Clinical Trial
Annals of the Rheumatic Diseases 2015;74:778.